Insilico Medicine
PrivateLast Round
IPO
Dec 30, 2025
Est. Valuation
$1.72B
Total Funding Raised
$854.01M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Insilico Medicine is a biotechnology company that develops an advanced AI platform and innovative drugs aimed at providing transformative solutions for cancer, fibrosis, immune disorders, central nervous system diseases, and age-related conditions.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Revenue Share
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Insilico Medicine Comparables
Compare Insilico Medicine with similar companies based on industry and business-model similarity.
Insilico Medicine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Dec 30, 2025 | ||||
| Series E | Jun 16, 2025 | ||||
| Series E | Mar 13, 2025 | ||||
| Series E | Jan 7, 2025 | ||||
| Debt | Nov 5, 2024 | ||||
Series D Extension | Aug 11, 2022 |
Key People
Founding team and executive leadership
Insilico Medicine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series C, Series D Extension |
| AIBasis Fund | Series C |
| Credit Suisse Asset Management | ipo |
| Temasek | ipo |
| Lake Bleu Capital | Series C |
| Winter Capital | Series C |
| 上海浦东创业投资有限公司 | Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 30, 2026
Unified AI framework integrates TargetPro and TargetBench for improved drug development.
- Mar 24, 2026
Partnered with ASKA Pharmaceutical Co., Ltd. for drug discovery.
Recent news
Latest coverage and updates
- is_developingSep 9, 2026
Insilico Medicine, Inc. is developing drug rentosertib on Sep 9th '26.
- has_earningsSep 3, 2026
Insilico Medicine, Inc. had earnings of $51M on Apr 1st '26.
- has_revenueSep 3, 2026
Insilico Medicine, Inc. had revenue of $106M on Apr 1st '26.
- launchesAug 24, 2026
Insilico Medicine, Inc. launches drug candidate for idiopathic pulmonary fibrosis.
- launchesAug 17, 2026
Insilico Medicine, Inc. launched 'ai+life sciences' CVC fund on Aug 18th '26.
Insilico Medicine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Insilico Medicine's valuation, stock price, and market status.
Is Insilico a public or private company?
Insilico is a private company.
What is the current stock price of Insilico?
Insilico is a private company with no public stock price. No recent secondary market data is available.
How much is Insilico worth (valuation)?
Insilico's valuation is estimated at $1.7B based on funding round data.
Can I buy Insilico stock?
Insilico shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Insilico's last funding round?
Insilico's most recent funding round was ipo on December 30, 2025.
Who are the main investors in Insilico?
Key investors in Insilico include 上海浦东创业投资有限公司, China International Capital Corporation, Counterpoint Global (Morgan Stanley), Aramco Ventures, Value Partners Group.
Will Insilico IPO soon?
No public IPO plans have been announced for Insilico.
How can I track Insilico secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Insilico's secondary market activity and sign up for updates.